KTTA
Pasithea Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.58
−0.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 473.0K | — | — | — | 5.1K |
| Gross Profit | (473.0K) | — | — | — | (5.1K) |
| Operating Expenses | |||||
| R&D Expense | 6.6B | 8.0M | 7.2M | 8.1M | 2.7M |
| SG&A Expense | 4.0B | 12.9M | 7.1M | 7.9M | 9.9M |
| General & Admin Expense | 4.0B | 12.9M | 7.1M | 7.9M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (10.6B) | — | — | — | — |
| Total Operating Expenses | 23.5M | 20.9M | 14.2M | 16.0M | 12.6M |
| Cost and Expenses | 24.0M | 20.9M | 14.2M | 16.0M | 12.6M |
| Operating Income (EBIT) | (24.0M) | (20.9M) | (14.2M) | (16.0M) | (12.6M) |
| Non-Operating | |||||
| Interest Income | 1.1M | 327.2K | 423.2K | 415.4K | — |
| Interest Expense | — | — | — | — | 102.00 |
| Net Interest Income | 1.1M | 327.2K | 423.2K | 415.4K | (102.00) |
| Other Non-Op Income/Expense | 2.7M | 429.6K | 345.4K | 471.6K | 861.1K |
| Non-Operating Income (excl Interest) | — | — | — | — | (861.1K) |
| EBT (Pre-Tax Income) | (21.3M) | (20.4M) | (13.9M) | (15.5M) | (11.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (21.3M) | (20.4M) | (13.9M) | (16.0M) | (13.9M) |
| Earnings from Cont. Ops | (21.3M) | (20.4M) | (13.9M) | (15.5M) | (11.7M) |
| Earnings from Discont. Ops | — | — | — | (453.9K) | (2.2M) |
| Bottom Line Net Income | (21.3M) | (20.4M) | (13.9M) | (16.0M) | (13.9M) |
| Per Share | |||||
| Basic EPS | ($2.46) | ($2.91) | ($12.69) | ($13.01) | ($10.34) |
| Diluted EPS | ($2.46) | ($2.91) | ($12.69) | ($13.01) | ($10.34) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 7.0M | 7.0M | 1.1M | 1.2M | 1.3M |
| Diluted Shares Outstanding | 7.0M | 7.0M | 1.1M | 1.2M | 1.3M |
| Profitability Metrics | |||||
| EBITDA | (23.3M) | (20.2M) | (13.6M) | (15.3M) | (11.7M) |
| D&A | 654.2K | 662.6K | 649.0K | 648.5K | 5.1K |
| EBIT | (24.0M) | (20.9M) | (14.2M) | (16.0M) | (11.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026